Business
ESM Schedule 1 update
ESM Schedule 1 update.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 6497L Venn Life Sciences Holdings PLC 13 January 2016 \n\nPre-Admission AnnouncementESM Schedule 1\n\n\n\n\nAnnouncement to be made by the ESM Applicant prior to admission in accordance with\nrule 2 of the ESM Rules for Companies\n\n\n\n\n\nAll Applicants must complete the following\n\n\n\n \n\n\n\n\nCompany name Venn Life Sciences Holdings plc (\"Venn Life Sciences\" or the \"Company\")\n\n\n\n\n\n\n\nCompany registered address and if different, company trading address (including postcodes)\n\n\n\n\nRegistered Office: 1 Berkeley Street, London, WIJ8DJ, UK\n \n\n\n\n\nCountry of incorporation England and Wales\n\n\n\n\n\n\n\nCompany website address containing all information required by rule 26 in the ESM Rules\nfor Companies\n\n\n\n\nhttp://www.vennlifesciences.com/investor-aim-rules/ \n\n\n\n\nCompany business (including main country of operation) or, in the case of an investing company, details of its investing strategy. If the admission is sought as a result of a reverse takeover under rule 14 of the ESM Rules for Companies, this should be stated\n\n\n\n\n \nVenn Life Sciences is a European Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn offers clients a full spectrum of services form non-clinical through all clinical phases. Venn also has an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science. Venn's current capabilities have developed through a combination of acquisitions and organic growth. Venn expects to continue to develop in this way and intends broadening it's footprint further in Europe. \n \nVenn Life Sciences is headquartered in Dublin, Ireland and has subsidiaries operating in France, Germany, the Netherlands and the UK (together the \"Group\").\n \n\n\n\n\nDetails of securities to be admitted including any restrictions as to transfer of securities (i.e. where known, number of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares)\n\n\n\n\nThe total number of ordinary share...